Industry-Leading Cell and Gene Therapy Solutions Provider, Emerging Therapy Solutions (ETS), Expands Leadership Team
ETS builds for cell and gene therapy market continued growth and for the future.
BLOOMINGTON, Minn., July 13, 2022 – Emerging Therapy Solutions® (ETS) announced, in line with its future growth strategy, Surya Singh, MD has assumed the role of Senior Vice President (SVP), Medical Delivery Services and Chief Medical Officer (CMO) of the Minneapolis-based company, Tim Michaels has joined ETS in the role of SVP, Insurance Risk Services, and Ashley Hume has been promoted to SVP, Strategic Growth and Client Engagement, all part of a company structure update tied to the company’s strategic plans.
Dr. Singh will be responsible for leading the ETS medical services and network contracting teams as the company continues to expand its relationships with medical centers throughout the US, particularly those that provide specialty and high-cost treatments such as cell and gene therapies. Dr. Singh will also work closely with bio pharma companies on behalf of ETS, sharing his clinical expertise to help expand relationships and programs that benefit ETS stakeholders.
Tim Michaels will assume responsibility for ETS’ pipeline risk forecast modeling and tools, building on existing work, with plans to add new services and programs in the coming months as the team expands. Tim will work closely with Ashley Hume, who assumes additional responsibility for all client service teams, and who will continue to drive product and service development and deployment, along with building on ETS’ dedication to excellence in providing the best in customer experience and value.
According to David J. McLean, PhD, Co-founder and CEO of ETS, the new leadership roles are part of a recent reorganization that will expertly position the growing company to support its clients as they prepare for the changes needed in the healthcare insurance industry driven by increasing numbers of high-cost treatments, including those anticipated for hemophilia A, sickle cell disease and many others.
“I’m pleased and excited about the incredible additional opportunities afforded ETS through the new structure and through the addition of our newest leaders,” said McLean. “We’ve had the benefit of Dr. Singh as an advisor to ETS since the beginning, so he already knows our business and services. Now we can benefit from his hands-on involvement, clinical and bio pharma expertise, and his strong leadership. Coupled with Tim’s technology, finance, and forecasting/risk background and Ashley’s client relationships and innovation focus, we have even greater in-house capabilities to benefit our clients.”
Dr. Singh has been a senior advisor to non-profits, private corporations, and publicly-traded companies, and previously was corporate vice-president and CMO at CVS Health Specialty, CMO and head of product at Proventys, (acquired by McKesson Corporation), CMO at D2Hawkeye (now Verisk Health) and was a consultant at McKinsey and Company. Dr. Singh is board certified in internal medicine and formerly practiced as a hospitalist physician at the Brigham & Women’s Hospital and was also an adjunct instructor of medicine at Harvard Medical School and Harvard School of Public Health, where he continues to teach periodically.
“ETS is on the cutting edge of industry preparation and change, and I’m thrilled to step more fully into being part of creating the solutions this industry needs,” shared Singh. “Medical centers and bio pharma companies are a critical component of the value ETS delivers to members and payers – whether as part of our ETS Programs of Excellence and Programs of Experience models, through our expert clinical panels, or through our facility certification work – we are ahead of the market in what we offer. I’m excited to dig in and help build the connective tissue our industry needs to really make this work.”
Tim Michaels has thirty years of experience working with payers, providers, medtech and service companies, including notable healthcare companies such as UnitedHealth Group, Kaiser Permanente, Cedars-Sinai Health System, Ascension, Mayo Clinic, and BlueCross BlueShield of Minnesota. Tim brings strong expertise in financial budgeting, forecasting and risk management and was most recently CEO of RabbitHole Equity. Previously, Tim held executive positions at Grant Thornton LLP, Pricewaterhouse- Coopers LLP, and with Optum.
Ashley Hume is a 25-year veteran in the healthcare and managed care industries. Ashley joined ETS in 2019 as an original founding member responsible for client relationships and developing the ETS service portfolio and business platform. Prior to ETS, Ashley was director of provider relations for Blue Cross and Blue Shield of Minnesota, vice president of operations for NovoLogix, and led revenue cycle operations and contracting for multiple specialty groups and facilities.
Known for its industry expertise in cell and gene therapies, ETS provides premier end-to-end solutions to help payers manage the immense cost, high risk and intricate processes associated with treating complex and costly medical conditions. ETS services include pipeline monitoring, expert clinical and medical coverage content and education; network management and access to ETS negotiated rates at medical center Programs of Excellence; accurate and timely claims repricing; and actuarial data analytics and reporting. ETS has established relationships at over 120 medical centers and over 1,000 programs designed to support the individual administration of cell and gene therapies, solid organ and bone marrow transplants, and other specialty services. ETS also helps payers with the plan design, analytics, clinical data modeling, and policy design related to high-cost conditions.
About Emerging Therapy Solutions
Emerging Therapy Solutions® (ETS) helps healthcare payers – including reinsurance and stop-loss payers, health plans and self-funded employers – manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.
For more information about ETS or media inquiries, please contact:
Vice President, Marketing
Emerging Therapy Solutions